Please provide your email address to receive an email when new articles are posted on . Continuous cough monitoring allows for assessment of immediate treatment effects in patients with refractory ...

About 4% to 10% of the adult population experiences chronic cough — a cough lasting eight weeks or more, or at least four weeks for children. A chronic cough doesn't call for immediate medical ...

ORLANDO, Fla. — Asthma is the most common cause of chronic cough in children, but it’s important to be aware of other differential diagnoses for those patients who have less common concerns, according ...

Chronic cough took center stage at the European Respiratory Society (ERS) Congress session titled "Conditions We Are Just Dealing With the Tip of the Iceberg in Primary Care: Frequently Mismanaged ...

Please provide your email address to receive an email when new articles are posted on . Most cases are benign and resolve spontaneously. The most common causes are post-infectious, asthma or ...

STATE COLLEGE, Pa. (WPVI) -- A cough is supposed to protect the lungs and windpipe from irritants. But coughs that go on and on can be annoying - or signs of bigger problems. Chronic coughs can have ...

Add Yahoo as a preferred source to see more of our stories on Google. Even if it's not accompanied by other symptoms, battling an ongoing cough can be annoying. Whether you’re coughing constantly or ...

HONOLULU (KHON2) — A chronic cough can often times be a headache to deal with, especially if it interferes with your daily activities. Sometimes, it may be difficult to find out what’s causing it. Get ...

Chronic cough is among the most common reasons for seeking medical care, with middle-aged women the group most affected. New studies also show that this condition appears to be a hereditary phenomenon ...

The combined impact of respiratory illness such as COPD, asthma, chronic cough and pneumonia on individuals and health systems is staggering. COPD alone affects more than 15 million people and costs ...

Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced that its Phase 2b ASPIRE trial ...

The FDA declined to approve oral gefapixant for treating chronic cough, Merck announced on Wednesday. In its complete response letter, "the FDA concluded that Merck's application did not meet ...